Ultragenyx Pharmaceutical Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Okay. Well, thank you, everyone. My name is Gena Wang. I'm a SMid cap biotech analyst at Barclays.
It is my great pleasure to introduce our next presenting company, Ultragenyx. On the screen with me is Emil Kakkis, President and Chief Executive Officer and a Co-Founder of the company.
Emil, I will hand it over to you.
Well, thank you, Gena. Thank you for having us on the call today. Happy to be -- give you a brief update on Ultragenyx for just a couple of minutes, and then we can go into any questions you may have.
It's been a remarkable year for Ultragenyx as a company. It's our tenth year since founding. And in that year, we completed 2 product approvals for Dojolvi and the TIO indication for Crysvita. We continue to manage the significant launch of both products that we were approved and now the 2 products and despite the COVID situation. We attribute it to our field teams and the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |